Celldex reported positive Phase 2b data showing sustained effects of Barzolvolimab in treating angioedema in patients with chronic spontaneous urticaria. The update supports the drug candidate's clinical profile and is a constructive development for the company’s pipeline. The news is positive for sentiment, though the market impact should be limited unless additional efficacy or regulatory milestones follow.
Celldex reported positive Phase 2b data showing sustained effects of Barzolvolimab in treating angioedema in patients with chronic spontaneous urticaria. The update supports the drug candidate's clinical profile and is a constructive development for the company’s pipeline. The news is positive for sentiment, though the market impact should be limited unless additional efficacy or regulatory milestones follow.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
